Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy
More than 4,400 patients in the OPTIMA trial had nearly identical outcomes when lower-risk cases skipped chemotherapy, researchers said.
- The Optima trial observed more than 4,400 patients aged 40 or older with hormone-sensitive breast cancer, revealing that 93.6% treated with hormone therapy alone remained recurrence-free after five years, comparable to 94.8% who also received chemotherapy.
- Participants utilized the Prosigna genomic test measuring gene activity to stratify treatment; those scoring above 60 received chemotherapy plus hormone therapy, while those scoring 60 or below received hormone therapy alone, yielding similar outcomes regardless of chemotherapy use.
- Karen Bonham, 64 from Cardiff, avoided chemotherapy after her Prosigna test returned a low score, saying the trial "helped decision making to allow me to receive targeted, appropriate treatment" and has returned to normal family life.
- Co-Chief investigator Iain MacPherson of the University of Glasgow said The Optima provides "robust, practice-changing evidence" that clinicians can safely reduce chemotherapy use for many patients with hormone-sensitive breast cancer.
- Researchers noted more studies are required to determine if Prosigna offers similar benefits for men and patients aged under 40, ensuring treatment decisions remain driven by evidence across all demographic groups.
7 Articles
7 Articles
Genomic test may help breast cancer patients safely skip chemotherapy
A genomic test could help thousands of breast cancer patients avoid chemotherapy without compromising their outcomes, according to results from a large international phase III clinical trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, known as OPTIMA, enrolled more than 4,400 patients with hormone receptor-positive, HER2-negative early breast cancer. This subtype accounts for the majority o…
The Independent
Western Morning NewsMillions of breast cancer patients could avoid chemotherapy with new genome test
Doctors said the test shows people with certain forms of the disease can safely avoid chemotherapy
Genomic Testing May Help Many Hormone-Sensitive Breast Cancer Patients Avoid Chemotherapy: UCL Study
A recent clinical trial, spearheaded by University Coll […] The post Genomic Testing May Help Many Hormone-Sensitive Breast Cancer Patients Avoid Chemotherapy: UCL Study first appeared on GeneOnline News. The post Genomic Testing May Help Many Hormone-Sensitive Breast Cancer Patients Avoid Chemotherapy: UCL Study appeared first on GeneOnline News.
Scienmag: Latest Science and Health News
BIOENGINEER.ORGGene Testing Safely Spares Many Breast Cancer Patients from Chemotherapy
A transformative clinical trial led by University College London (UCL) has unveiled compelling evidence that numerous individuals diagnosed with hormone-sensitive breast cancer can safely circumvent chemotherapy by utilizing an advanced genomic testing approach. This finding heralds a significant shift in oncological treatment paradigms, potentially sparing thousands from the debilitating side effects associated with chemotherapy without heighte…
Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients’ Access to Clinical Trials
AI-powered trial matching now available through two trusted cancer advocacy and navigation platformsBOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Can... L'articolo Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients’ Access to Clinical Trials è un contenuto originale di 01net.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
